Free Trial
→ What’s Elon building now? (From Paradigm Press) (Ad)tc pixel
NASDAQ:INTS

Intensity Therapeutics Q3 2026 Earnings Date & Estimates

Intensity Therapeutics logo
$3.63 -0.05 (-1.36%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$3.62 -0.01 (-0.28%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intensity Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 11, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Intensity Therapeutics in Q3 2026

Intensity Therapeutics is expected to post earnings of -$0.94 per share. In the same quarter a year earlier Intensity Therapeutics reported -$1.50 per share. Intensity Therapeutics last reported on August 11, 2026, posting -$1.11 per share and missing the -$0.8725 consensus estimate. Intensity Therapeutics has beaten the consensus EPS estimate in 2 of its last 6 quarters.

Consensus Estimates

Consensus EPS
-$0.94
Prior-Year EPS
-$1.50

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.11 (Missed by -$0.2375)
EPS Beat Rate
2 of last 6 quarters

Prepare for the Q3 2026 Call

Intensity Therapeutics Q3 2026 Earnings FAQ

Intensity Therapeutics (NASDAQ:INTS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Intensity Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Intensity Therapeutics to post earnings of -$0.94 per share for Q3 2026.

Intensity Therapeutics Earnings Headlines

Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Rated "Moderate Buy" by Wall Street Analysts
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085789
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/intensity-therapeutics-to-participate-in-the-hc-wainwright-28th-annual-global-investment-conference-302868720.html
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
October 10 at 1:00 AM  |  Behind the Markets (Ad)
Intensity's Q2 Loss Widens Marginally As Trials For Breast Cancer Drug Resume
September 4, 2026  |  rttnews.comhttps://www.rttnews.com/3688592/intensity-s-q2-loss-widens-marginally-as-trials-for-breast-cancer-drug-resume.aspx
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/intensity-therapeutics-ints-q2-2026-015749930.html
Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4630932-intensity-therapeutics-targets-invincibleminus-4-enrollment-completion-by-end-of-2027-while
See More Intensity Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email.

About Intensity Therapeutics

Intensity Therapeutics (NASDAQ:INTS), Inc. is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors. The company’s approach is based on its proprietary INTASYL technology, which is intended to enable therapeutic compounds to enter tumor cells directly, promote cancer-cell death and stimulate an immune response against tumor tissue.

Intensity Therapeutics’ lead investigational product, INT230-6, is an intratumoral therapy formulated to deliver anticancer agents directly into tumors. The company is evaluating the candidate as a potential treatment for various solid tumors, both as a standalone therapy and in combination with immune checkpoint inhibitors. Its development strategy is intended to generate a local tumor response while also helping the immune system recognize and attack cancer cells elsewhere in the body.

The company’s activities are focused on research, clinical development and potential commercialization of its INTASYL-based immunotherapies. Intensity Therapeutics is headquartered in Shelton, Connecticut, and its programs are being advanced through clinical studies and research collaborations in oncology.

View Intensity Therapeutics Profile
Earnings Tools